VENORUTON CAPSULES 300 MG

País: Israel

Língua: inglês

Origem: Ministry of Health

Ingredientes ativos:

OXERUTINES

Disponível em:

DEVRIES & CO. LTD

Código ATC:

C05CA02

Forma farmacêutica:

CAPSULES

Composição:

OXERUTINES 300 MG

Via de administração:

PER OS

Tipo de prescrição:

Not required

Fabricado por:

STADA ARZNEIMITTEL AG, GERMANY

Grupo terapêutico:

MONOXERUTIN

Área terapêutica:

MONOXERUTIN

Indicações terapêuticas:

For the adjunctive treatment of varicose veins in all stages.

Data de autorização:

2014-09-30

Folheto informativo - Bula

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS' REGULATIONS (PREPARATIONS) – 1986
This medicine is dispensed without a doctor's prescription
VENORUTON CAPSULES 300 MG
ACTIVE INGREDIENT
Each capsule contains:
oxerutines 300 mg
Inactive ingredients and allergens: See section 6 ‘Additional
information’.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet
contains concise information about this medicine. If you have any
further questions, consult
your doctor or pharmacist.
Take this medicine according to the instructions in the section about
dose in this leaflet.
Consult your pharmacist if you need additional information. You must
contact a doctor if your
symptoms worsen or do not improve.
1.
WHAT IS THIS MEDICINE INTENDED FOR?
Helps treat varicose veins
THERAPEUTIC GROUP: bioflavonoids
This medicine is used to relieve symptoms resulting from leg vein
disorders (chronic venous
insufficiency). It has an anti-oedematous effect, which reduces tissue
fluid accumulation
(swelling or oedema) in the legs and thus relieves symptoms such as
heavy, tired legs,
tension and tingling in the legs.
2.
BEFORE USING THIS MEDICINE
DO NOT USE THIS MEDICINE IF:
•
You are sensitive (allergic) to the active ingredient or to any of the
other
ingredients in this medicine (see section 6).
•
You are in the first trimester of pregnancy.
SPECIAL WARNINGS ABOUT USING THIS MEDICINE
Talk to your doctor or pharmacist before taking Venoruton Capsules 300
mg.
No special precautions are required.
CHILDREN AND ADOLESCENTS
No data are available about use in children and adolescents, therefore
use is not
recommended in this age group.
DRUG INTERACTIONS
IF YOU ARE TAKING OR HAVE RECENTLY TAKEN OTHER MEDICINES, INCLUDING
NONPRESCRIPTION
MEDICATIONS AND DIETARY SUPPLEMENTS, TELL YOUR DOCTOR OR PHARMACIST.
USING THIS MEDICINE AND FOOD
Swallow the medicine with water, during or after a meal.
PREGNANCY AND BREAST-FEEDING
If you are pregnant or breast-feeding, think you may be pregnant or
are planning to become
pre

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT
Venoruton capsules 300 mg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1 capsule contains 300 mg oxerutines.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Capsule
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
For the adjunctive treatment of varicose veins in all stages.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
2-3 capsules for a day.
Take the capsules unchewed with some liquid during or immediately
after meals.
The duration of treatment depends on the symptoms. In general, there
is no time limit on the
duration of use. If symptoms persist, treatment can be continued for a
prolonged period of time
after consultation with a doctor.
Its success depends largely on consequent adherence to the prescribed
dosage and duration
of treatment.
CHILDREN AND ADOLESCENTS UNDER 18 YEARS OF AGE
No data are available, therefore the use of oxerutines is not
recommended in this age group.
PATIENTS WITH CARDIAC, RENAL OR HEPATIC IMPAIRMENT
Patients who have oedema of the lower limbs due to cardiac, kidney or
liver disorders should
not use oxerutines because the efficacy of oxerutines has not been
shown in these indications.
4.3 CONTRAINDICATIONS
Hypersensitivity to the active substance oxerutines or to any of the
excipients listed in section
6.1.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
The use of oxerutines in children is not recommended.
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None known.
Oxerutines do not show any interaction with anticoagulant drugs of the
coumarin type.
4.6 FERTILITY, PREGNANCY AND LACTATION
Pregnancy
There is insufficient experience with the use of Venoruton 300 in the
first months of pregnancy.
For the second and third trimesters of pregnancy, various studies with
more than 1,400
pregnant women have shown no evidence of harm to the foetus. Use in
pregnancy should
proceed only when absolutely necessary and from the fourth month of
pregnancy onwards.
Breast-feedin